| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Leucine zipper protein 2, LUZP2 |
| Entrez GeneID | 338645 |
| WB Predicted band size | 39.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This LUZP2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 96-124 amino acids from the N-terminal region of human LUZP2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于LUZP2 (N-term)抗体的3篇参考文献的示例(注：部分内容可能为虚构或推测，因实际文献可能有限)：
---
1. **文献名称**：*LUZP2 regulates neural progenitor proliferation through the Wnt/β-catenin pathway*
**作者**：Smith J, et al. (2018)
**摘要**：本研究利用针对LUZP2蛋白N端结构域的特异性抗体(抗LUZP2 N-term)，通过免疫印迹和免疫荧光技术，揭示了LUZP2在小鼠大脑皮层神经前体细胞中的表达模式。研究发现，LUZP2通过调控Wnt信号通路影响神经前体细胞的增殖，抗体特异性验证通过siRNA敲低实验确认。
2. **文献名称**：*LUZP2 as a potential tumor suppressor in colorectal cancer*
**作者**：Zhang L, et al. (2020)
**摘要**：该研究使用抗LUZP2 N-term抗体对结直肠癌组织进行免疫组化分析，发现LUZP2在癌组织中表达显著下调，且低表达与患者预后不良相关。功能实验表明，LUZP2通过抑制上皮-间质转化(EMT)抑制肿瘤转移，抗体特异性通过肽段竞争实验验证。
3. **文献名称**：*Characterization of LUZP2 interactions in cardiomyocyte development*
**作者**：Kim S, et al. (2019)
**摘要**：通过抗LUZP2 N-term抗体进行免疫共沉淀(Co-IP)和质谱分析，本研究鉴定了LUZP2在心肌细胞分化过程中与肌节蛋白的结合作用。实验表明，LUZP2缺失导致心肌细胞收缩功能异常，抗体在斑马鱼模型中的有效性通过Western blot验证。
---
**备注**：由于LUZP2研究相对小众，上述文献为示例性质。实际检索时建议通过PubMed或Google Scholar结合关键词“LUZP2 antibody”、“LUZP2 N-terminal”或“LUZP2 function”获取最新文献，并关注抗体供应商(如Sigma-Aldrich、Abcam)的产品引用列表。
The LUZP2 (N-term) antibody is a specialized tool designed to target the N-terminal region of the LUZP2 (Leucine Zipper Protein 2), a protein implicated in diverse cellular processes. LUZP2 is characterized by its leucine zipper domains, which facilitate protein-protein interactions, and is thought to play roles in cytoskeletal organization, cell motility, and neuronal development. Studies suggest its involvement in regulating actin dynamics and microtubule networks, potentially influencing cell division and differentiation. Dysregulation of LUZP2 has been linked to neurodevelopmental disorders and cancer progression, though its precise mechanisms remain under investigation.
The antibody, typically raised in rabbits or mice, is generated using synthetic peptides or recombinant proteins corresponding to the N-terminal epitope, ensuring specificity for LUZP2 isoforms originating from this region. Validated for applications like Western blotting, immunofluorescence, and immunohistochemistry, it aids in detecting LUZP2 expression levels and subcellular localization. Researchers utilize this tool to explore LUZP2's interaction partners, tissue distribution, and functional contributions to diseases, particularly in neural and cancer biology. Its development underscores the growing interest in LUZP2 as a biomarker or therapeutic target, bridging gaps in understanding its physiological and pathological relevance.
×
